Journal article icon

Journal article

Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial

Abstract:

Objectives

To evaluate the safety and tolerability of the intravenous administration of Cx611, a preparation of allogeneic expanded adipose-derived stem cells (eASCs), in refractory rheumatoid arthritis (RA) patients, as well as to obtain preliminary clinical efficacy data in this population.

Methods

Multicentre, dose escalation, randomised, single-blind (double-blind for efficacy), placebo controlled, phase Ib/IIa clinical trial. Patients with active refractory RA...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1136/annrheumdis-2015-208918

Authors


Álvaro-Gracia, JM More by this author
García-Vicuña, R More by this author
Carreño, L More by this author
Expand authors...
Publisher:
BMJ Publishing Group Publisher's website
Journal:
Annals of Rheumatic Diseases Journal website
Publication date:
2016-05-05
DOI:
URN:
uuid:7a38312b-b7c5-4c50-be61-8db96a5ca19a
Source identifiers:
624915
Local pid:
pubs:624915

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP